

<GHWSYK _d (MaGC)LRPG-NH ₂ (SEQ ID NO:13)	6.83 (95%)	7.07 ^c (95%)
<GHYSYLK(PtscGDap)WKPG-NH ₂ (SEQ ID NO:11)	7.08 (96%)	6-8 ^e (90%)
<GHYSLK(azaGGC)WKPG-NH ₂ (SEQ ID NO:7)	6.60 (100%)	6.47 ^c (99%)
Nal _d Cpa _d W _d SRK _d (PtscGC)WKPG-NH _d (SEQ ID NO:12)	8.43 (97%)	

✓ Page 47, lines 10-14:

IMP3, (<GHWSYK(MaGC)LRPG amide) (SEQ ID NO:6) was synthesized as above. IMP₃

B20 has a retention time of 6.4 min on a reversed phase C-18 column using a gradient of 0-100% B in 10 min at a flow rate of 3 ml/min where A is 0.1% TFA in H₂O and B is 90% CH₃ CN, 0.1% TFA.

✓ *NE* Page 55 (at the end of the specification, insert)

B21 the printed Sequence Listing submitted concurrently herewith.

IN THE CLAIMS:

Subs C3 Claim 41 (Amended). A peptide according to claim 1, wherein said peptide is selected from the group consisting of:

(Chel)γAbuNleDHF_d RWK-NH₂, (SEQ ID NO:1)

(Chel)γAbuHSDAVFTDNYTRLRKQMAVKKYLNSILN-NH₂, (SEQ ID NO:2) - 7.

KPRRPYTDNYTRLRK(Chel)QMAVKKYLNSILN-NH₂, (SEQ ID NO:3)

(Chel)γAbuVFTDNYTRLRKQMAVKKYLNSILN-NH₂, (SEQ ID NO:4)

(Chel)γAbuYTRLRKQMAVKKYLNSILN-NH₂, (SEQ ID NO:5)

B22 HSDAVFTDNYTRLRK(Chel)QMAVKKYLNSILN-NH₂, (SEQ ID NO:2) - 7.

(SEQ ID NO:6) <GHWSYK(Chel)LRPG-NH₂, <GHYSLK(Chel)WKPG-NH₂, (SEQ ID NO:7)

AcNal_d Cpa_d W_d SRK_d (Chel)LRPA_d-NH₂, (SEQ ID NO:8)

(SEQ ID NO:9) (Chel)γAbuSYSNleDHF_d RWK-NH₂, (Chel)γAbuNleDHF_d RWK-NH₂, (SEQ ID NO:1) *represented*

(Chel)NleDHF_d RWK-NH₂, (SEQ ID NO:1) *represented*

Ac-HSDAVFTENYTKLRK(Chel)QNleAAKKYLNDLKKGGT-NH₂, (SEQ ID NO:10)

(Chel)γAbuHSDAVFTDNYTRLRKQMAVKKYLNSILN-NH₂, (SEQ ID NO:2) - 7.

(Chel)γAbuVFTDNYTRLRKQMAVKKYLNSILN-NH₂, (SEQ ID NO:4) - 7.

3+ (SEQ ID NO:1) (Chel)γAbuNleDHF_d RWK-NH₂, <GHWSYK(Chel)LRPG-NH₂, (SEQ ID NO:6)

(SEQ ID NO:7) <GHYSLK(Chel)WKPG-NH₂, AcNal_d Cpa_d W_d SRK_d (Chel)LRPA_d-NH₂, (SEQ ID NO:8)

(SEQ ID NO:11) <GHYSYLK(Chel)WKPG-NH₂, <GHYSLK(Chel)WKPG-NH₂, (SEQ ID NO:9)

(SEQ ID NO:12) Nal_d Cpa_d W_d SRK_d (Chel)WKPG-NH₂, <GHWSYK_d (Chel)LRPG-NH₂, (SEQ ID NO:13)

AcNal_d Cpa_d W_d SRK_d (Chel)LRPA_d-NH₂, (SEQ ID NO:8)

AcNal_d Cpa_d W_d SRK_d (Chel)LRPA_d-NH₂, (SEQ ID NO:8)

(SEQ ID NO:8) AcNal_d Cpa_d W_d SRK_d (Chel)LRPA_d-NH₂, <GHWSYK(Chel)LRPG-NH₂, (SEQ ID NO:6)

(SEQ ID NO:14) AcK(Chel)F_d CFW_d KTCT-OH, AcK(Chel)DF_d CFW_d KTCT-OH, (SEQ ID NO:15)

(SEQ ID NO:14) AcK(Chel)F_d CFW_d KTCT-ol, AcK(Chel)DF_d CFW_d KTCT-ol, (SEQ ID NO:15)

(SEQ ID NO:16) (Chel)DF_d CFW_d KTCT-OH, K(Chel)DF_d CFW_d KTCT-ol, (SEQ ID NO:15)

(SEQ ID NO:17) K(Chel)KKF_d CFW_d KTCT-ol, K(Chel)KDF_d CFW_d KTCT-OH, (SEQ ID NO:18)

(SEQ ID NO:19) K(Chel)DSF_d CFW_d KTCT-OH, K(Chel)DF_d CFW_d KTCT-OH, (SEQ ID NO:15)

(SEQ ID NO:20) K(Chel)DF_d CFW_d KTCD-NH₂, K(Chel)DF_d CFW_d KTCT-NH₂, (SEQ ID NO:15)

(SEQ ID NO:18) K(Chel)KDF_d CFW_d KTCT-NHNH₂, AcK(Chel)F_d CFW_d KTCT-NHNH₂, (SEQ ID NO:16)

(SEQ ID NO:14) K(Chel)F_d CFW_d KTCT-ol, and F_d CFW_d KTCTK(Chel)-NH₂, (SEQ ID NO:21)

wherein (Chel) is said radiometal-binding moiety.